During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

Effective from 1 October 2025, CMS and commercial health insurers will recognise the HCPCS Level II code A9616 assigned for reimbursement of Gozellix. The assignment of the code is a significant ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

One of the most common early signs of prostate cancer is trouble with urination. Urination is affected because the prostate ...

Dr. Kevin O’Connor invoked doctor-client privilege and his rights under the Fifth Amendment during an appearance before the ...

Prostate cancer is one of the most common cancers found in U.S. men. If detected early, prostate cancer is often highly treatable before it spreads. But the American Cancer Society estimates there ...